Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;21(Suppl 1):14–19. doi: 10.1002/clc.4960211304

Cardiac remodeling as a consequence and cause of progressive heart failure

Karla Kurrelmeyer 1, Dinesh Kalra 1, Biykem Bozkurt 1, Feng Wang 1, Ziad Dibbs 1, Yukihiro Seta 1, George Baumgarten 1, David Engle 1, Natarajan Sivasubramanian 1, Douglas L Mann 1,✉
PMCID: PMC6656235  PMID: 9853190

Abstract

Natural history studies in heart failure have shown that increases in left ventricular (LV) volume and LV mass are directly related to future deterioration in LV performance and a less favorable clinical course. Despite the recognized importance of remodeling in heart failure, very little is known about the basic mechanisms that lead to cardiac remodeling. In this review, we will summarize recent clinical and experimental studies that highlight the importance of the remodeling process during the progression of heart failure. The intent of this review is to provide an integrated view of the mechanisms that contribute to LV remodeling at the cellular level, the myocardial level, and the level of the chamber.

Keywords: left ventricular remodeling, heart failure, cardiac myocyte, apoptosis, necrosis

Full Text

The Full Text of this article is available as a PDF (718.1 KB).

References

  • 1. Leiden JM: The genetics of dilated cardiomyopathy: Emerging clues to the puzzle. N Engl J Med 1997; 337: 1080–1081 [DOI] [PubMed] [Google Scholar]
  • 2. Cohn JN: Structural basis for heart failure: Ventricular remodeling and its pharmacological inhibition. Circulation 1995; 91: 2504–2507 [DOI] [PubMed] [Google Scholar]
  • 3. Douglas PS, Morrow R, Ioli A, Reicheck N: Left ventricular shape, afterload, and survival in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1989; 13: 311–315 [DOI] [PubMed] [Google Scholar]
  • 4. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D: Left ventricular dilation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med 1997; 336: 1350–1355 [DOI] [PubMed] [Google Scholar]
  • 5. Linzbach AJ: Heart failure from the point of view of quantitative anatomy. Am J Cardiol 1960; March: 370–382 [DOI] [PubMed]
  • 6. Lowes BD, Minobe W, Abraham WT, Rizeq MN, Bohimeyer TJ, Quaife RA, Roden RL, Dutcher DL, Robertson AD, Voelkel NF, Badesch DB, Groves BM, Gilbert EM, Bristow MR: Changes in gene expression in the intact human heart: Downregulation of α‐myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest 1997; 100: 2315–2324 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Schaper J, Froede R, Hein S, Buck A, Hashizume H, Speiser B, Friedl A, Bleese N: Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. Circulation 1991; 83: 504–514 [DOI] [PubMed] [Google Scholar]
  • 8. Beuckelmann DJ, Nabauer M, Erdmann E: Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 1992; 85: 1046–1055 [DOI] [PubMed] [Google Scholar]
  • 9. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB: Decreased catecholamine sensitivity and β‐adrenergic‐receptor density in failing human hearts. N Engl J Med 1982; 307: 205–211 [DOI] [PubMed] [Google Scholar]
  • 10. Davies CH, Davia K, Bennett JG, Pepper JR, Poole‐Wilson PA, Harding SE: Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation 1995; 92: 2540–2549 [DOI] [PubMed] [Google Scholar]
  • 11. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBiano R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL: Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325: 1468–1475 [DOI] [PubMed] [Google Scholar]
  • 12. The Pimobendan in Congestive Heart Failure (PICO) Investigators : Effect of pimobendan on exercise capacity in patients with heart failure: Main results from the pimobendan in congestive heart failure (PICO) trial. Heart 1996; 76: 223–231 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Tsutsui H, Spinale FG, Nagatsu M, Schmid PG, Ishihara K, DeFreyte G, Cooper G, IV , Carabello BA: Effects of chronic β‐adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. J Clin Invest 1994; 93: 2639–2648 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Graybum PA, Eichhorn EJ: Time course of improvement in left venticular function, mass and geometry in patients with congestive heart failure treated with beta‐adrenergic blockade. J Am Coll Cardiol 1995; 25: 1154–1161 [DOI] [PubMed] [Google Scholar]
  • 15. Dipla K, Mattiello JA, Jeevanandam V, Houser SR, Margulies KB: Myocyte recovery after mechanical circulatory support in humans with end‐stage heart failure. Circulation 1998; 97: 2316–2322 [DOI] [PubMed] [Google Scholar]
  • 16. Josue O: Hypertrophie cardiaque causée par I'adrenaline et la toxine typhique. C R Soc Biol (Paris) 1907; 63: 285–290 [Google Scholar]
  • 17. Mann DL, Kent RL, Parsons B, Cooper G IV: Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992; 85: 790–804 [DOI] [PubMed] [Google Scholar]
  • 18. Tan LB, Jalil JE, Pick R, Janicki JS, Weber KT: Cardiac myocyte necrosis induced by angiotensin II. Circ REs 1991; 69: 1185–1195 [DOI] [PubMed] [Google Scholar]
  • 19. Missov E, Calzolari C, Pau B: Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997; 96: 2953–2958 [DOI] [PubMed] [Google Scholar]
  • 20. Narula, J , Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, Schmidt, U , Semigran MJ, Dec GW, Khaw B‐A: Apoptosis in myocytes in end‐stage heart failure. N Engl J Med 1996; 335: 1182–1189 [DOI] [PubMed] [Google Scholar]
  • 21. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Di Loreto C, Beltrami CA, Krajewski S, Reed JC, Anversa P: Apoptosis in the failing human heart. N Engl J Med 1997; 336: 1131–1141 [DOI] [PubMed] [Google Scholar]
  • 22. Cheng W, Li B, Kajstura J, Li P, Wolin MS, Sonnenblick EH, Hintze TH, Olivetti G, Anversa P: Stretch‐induced programmed myocyte cell death. J Clin Invest J 1995; 96: 2247–2259 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Leri A, Claudio PP, Li Q, Wang X, Reiss K, Wang S, Malhotra A, Kajstura J, Anversa P: Stretch‐mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin‐angiotensin system and decreases the Bcl‐2‐to‐Bax protein ratio in the cell. J Clin Invest 1998; 101: 1326–1342 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL, Glembotski CC, Quintana PJE, Sabbadini RA: Tumor necrosis factor alpha‐induced apoptosis in cardiac myocytes: Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996; 98: 2854–2865 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, Sonnenblick EH, Olivetti G, Anversa P: The cellular basis of dilated cardiomyopathy in humans. Mol Cell Cardiol 1995; 27: 291–305 [DOI] [PubMed] [Google Scholar]
  • 26. Jalil JE, Doering CW, Janicki JS, Pick R, Shroff SGS, Weber KT: Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 1989; 64: 1041–1050 [DOI] [PubMed] [Google Scholar]
  • 27. Weber KT: Extracellular matrix remodeling in heart failure. A role for de novo angiotensin II generation. Circulation 1997; 96: 4065–4082 [DOI] [PubMed] [Google Scholar]
  • 28. Weber KT, Brilla CG, Janicki JS: Myocardial fibrosis: Functional significance and regulatory factors. Cardiovasc Res 1993; 27: 341–348 [DOI] [PubMed] [Google Scholar]
  • 29. Weber KT, Sun Y, Guarda E: Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994; 23: 869–877 [DOI] [PubMed] [Google Scholar]
  • 30. Weber KT: Cardiac intersitium in health and disease: The fibrillar collagen network. J Am Coll Cardiol 1989; 13 (7): 1637–1652 [DOI] [PubMed] [Google Scholar]
  • 31. Weber KT, Pick R, Janicki JS, Lakier JB: Inadequate collagen tethers in dilated cardiopathy. Am Heart J 1988; 116: 1641–1646 [DOI] [PubMed] [Google Scholar]
  • 32. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley JA III, Spinale FG: Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end‐stage heart failure. Circulation 1998; 97: 1708–1715 [DOI] [PubMed] [Google Scholar]
  • 33. Tyagi SC, Kumar S, Voelker DJ, Reddy HK, Janicki JS, Curtis JJ: Differential gene expression of extracellular matrix components in dilated cardiomyopathy. J Cell Biochem 1996; 63: 185–198 [DOI] [PubMed] [Google Scholar]
  • 34. Bozkurt B, Kribbs S, Clubb Jr, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL: Pathophysiologically relevant concentrations of tumor necrosis factor‐α promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998; 97: 1382–1391 [DOI] [PubMed] [Google Scholar]
  • 35. Ross J Jr: Afterload mismatch in aortic and mitral valve disease: Implications for surgical therapy. J Am Coll Cardiol 1985; 5: 811–826 [DOI] [PubMed] [Google Scholar]
  • 36. Kono T, Sabbah HN, Rosman H, Alam M, Jafri S, Goldstein S: Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. J Am Coll Cardiol 1992; 20: 1594–1598 [DOI] [PubMed] [Google Scholar]
  • 37. Batista RJV, Santos JLV, Takeshita N, Bocchino L, Lima PN, Cunha MA: Partial left ventriculectomy to improve left ventricular function in end‐stage heart disease. J Cardiol Surg 1996; 11: 96–97 [DOI] [PubMed] [Google Scholar]
  • 38. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict CR, Shelton B: Effects of long‐term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Circulation 1995; 91: 2573–2581 [DOI] [PubMed] [Google Scholar]
  • 39. Sutton MSJ, Pfeffer MA, Plappert T, Rouleau J‐L, Moyé LA, Dagenais, GR , Lamar GA, Klein M, Sussex B, Goldman S, Menapace FJ Jr, Parker JO, Lewis S, Sestier F, Gordon DF, McEwan P, Bernstein V, Braunwald E: Quantitative two‐dimensional echocar‐diographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction: The protective effects of captopril. Circulation 1994; 89: 68–75 [DOI] [PubMed] [Google Scholar]
  • 40. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N: Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1998; 29: 1060–1066 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES